View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
April 27, 2017

Deals this week: EpimAb Biotherapeutics, Biohaven Pharmaceutical, Zai Lab (Shanghai)

Chinese-based biopharmaceutical company EpimAb Biotherapeutics has completed a series A venture financing round to raise funds required to advance its proprietary bispecific platform technology and develop a pipeline of candidates in immuno-oncology and other therapeutic areas.

Chinese-based biopharmaceutical company EpimAb Biotherapeutics has completed a series A venture financing round to raise funds required to advance its proprietary bispecific platform technology and develop a pipeline of candidates in immuno-oncology and other therapeutic areas.

The company has raised $25m from the round, which was led by Oriza Seed Venture Capital.

US-based biotechnology firm Biohaven Pharmaceutical Holding Company intends to raise between $116.67m and $133.33m through an initial public offering of shares of its common stock.

The company will offer approximately 8.33 million shares priced between $14 and $16 a share in the IPO.

Underwriters have a 30-day option to purchase up to an additional 1.25 million shares in case of any over-allotments.

"US-based biotechnology firm Biohaven Pharmaceutical Holding Company intends to raise between $116.67m and $133.33m through an initial public offering of shares of its common stock."

Chinese-based biopharmaceutical company Zai Lab (Shanghai) has signed a licensing agreement with US-based pharmaceutical company Paratek Pharmaceuticals for the development and commercialisation of the latter’s antibiotic, omadacycline, for Chinese patients.

The company will pay $7.5m upfront to Paratek, in addition to milestone-based payments based on the development and royalty payments based on sales.

US-based clinical-stage pharmaceutical company Karyopharm Therapeutics intends to raise $40m through an underwritten public offering of shares of its common stock in order to fund its clinical development, working capital and general corporate purposes.

Underwriters to the offering have a 30-day option to purchase additional shares worth up to $6m.

US-based clinical-stage medical dermatology and aesthetics company Sienna Biopharmaceuticals has completed a series B venture financing round led by ARCH Venture Partners and VenVest Capital to raise funds to advance its topical biotech pipeline.

The company has raised $40m from the financing round.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena